BACK
TO MAIN
PAGE

Nipah virus (NiV)

General Information

The case fatality rate is estimated at 40% to 75%. This rate can vary by outbreak depending on local capabilities for epidemiological surveillance and clinical management.

The 2018 annual review of the WHO R&D Blueprint list of priority diseases indicates that there is an urgent need for accelerated research and development for the Nipah virus.

There is no treatment or vaccine available against Nipah virus.

Transmission

Nipah virus is a zoonotic virus (it is transmitted from animals to humans) and can also be transmitted through contaminated food or directly between people. Fruit bats are the wildlife reservoir of Nipah virus. 

Symptoms

In infected people, it causes a range of illnesses from asymptomatic (subclinical) infection to acute respiratory illness and fatal encephalitis.

Show More

Epidemiology

2018

There have been a total 639 human cases of NiV infection reported from Bangladesh, India, Singapore, Philippines and Malaysia, with a mortality rate of about 59% until 2018.​

Vaccines
Pipeline

1
Vaccines in
the pipeline

Technology Platforms

  • mRNA (1)

DEVELOPMENT PHASES

  • Phase I (1)

TRIAL POPULATION

  • Adults (1)

Source: 
https://www.who.int/news-room/fact-sheets/detail/nipah-virus
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6830995
[Accessed: November 2022]

Vaccines Europe Pipeline Review

Download our pipeline review